Drug Profile


Alternative Names: CCR5/CCR2 antagonist; Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Imperial College of Science, Technology and Medicine; National Institute for Health Research; Tobira Therapeutics
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-alcoholic steatohepatitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Preclinical Cancer; Diabetic nephropathies; Graft-versus-host disease

Most Recent Events

  • 01 Nov 2016 Tobira Therapeutics has been acquired by Allergan
  • 24 Oct 2016 Interim efficacy and adverse event data from a phase IIb trial in Non-alcoholic steatohepatitis presented at the American Academy for the Study of Liver Diseases Annual Meeting (AASLD-2016)
  • 12 Sep 2016 Phase-I clinical trials in non-alcoholic steatohepatitis (Combination therapy, in volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top